Business context and reporting period
This is Celsus Therapeutics plc’s Form 10-K for the fiscal year ended December 31, 2014—not a standalone fourth-quarter report. The filing identifies the registrant as Celsus Therapeutics plc; the request metadata names Akari Therapeutics plc, so confirm the issuer and any subsequent name change before relying on this summary.
Celsus was a development-stage biopharmaceutical company with no product revenue. Its lead candidate, topical MRX-6, was in Phase 2 development for inflammatory skin conditions. OPT-1, CFX-1 and OAX-1 were preclinical-stage candidates. Research, manufacturing and clinical work relied substantially on outside providers.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $6.417 million | $1.276 million |
| General and administrative expense | $3.760 million | $2.330 million |
| Operating loss | $10.177 million | $3.606 million |
| Net loss | $9.648 million | $3.620 million |
| Net loss per ordinary share | $0.18 | $0.17 |
| Net cash used in operations | $9.461 million | $5.450 million |
| Cash and cash equivalents at year-end | $6.216 million | $7.657 million |
Amounts above are in U.S. dollars; the financial statements present amounts in thousands. Gross and operating margins are not meaningful because the company reported no revenue. Net loss widened substantially as development spending increased. R&D costs rose mainly with formulation, synthesis, manufacturing and clinical trial activity; G&A increases reflected professional fees, stock compensation, board fees, rent and insurance.
At December 31, 2014, total current assets were $6.431 million and current liabilities were $1.359 million. Shareholders’ equity was $4.853 million. The balance sheet reported no conventional borrowings; long-term liabilities included $235,000 of liabilities related to options and warrants and $33,000 of other long-term liabilities. Operating cash burn exceeded year-end cash, making additional financing important.
Financing activities provided $8.219 million in 2014, primarily from the February public offering. Investing activities used $199,000, including a $142,000 restricted deposit. The company reported a $30.190 million accumulated deficit. It had $1.456 million in disclosed lease obligations, largely for U.S. office space.
Material changes versus the prior comparable period
- Net loss increased to $9.648 million from $3.620 million, while R&D expense increased 403% to $6.417 million.
- Operating cash use increased 74% to $9.461 million. Year-end cash declined by $1.441 million despite equity financing.
- Ordinary shares outstanding rose to 55.636 million from 40.228 million, reflecting the 2014 offering and other share issuances.
- Financial results included $529,000 of net financial income in 2014, compared with $14,000 of net financial expense in 2013, primarily from fair-value changes in warrant and option liabilities.
Outlook, commentary, risks and unusual items
- Management expected continued losses and rising development expenses. It stated that additional capital would be required to complete development and pursue commercialization; the amount and timing of future financing were uncertain.
- The pediatric Phase 2 MRX-6 trial enrolled 74 patients, with a four-week blinded period and optional open-label extension. The filing anticipated completion of the blinded portion by the end of February 2015. FDA allowance of the MRX-6 IND was reported in January 2015.
- Earlier MRX-6 studies reported symptom improvement and no treatment-related adverse events, but were academic studies that did not meet FDA good clinical practice requirements. They are supportive evidence, not a substitute for compliant trials; future safety and efficacy are uncertain.
- Additional preclinical work on OPT-1, CFX-1 and OAX-1 was planned for 2015, subject to available resources. The company also described potential strategic licensing or partnering as part of its commercialization approach.
- Financing agreements included anti-dilution and most-favored-nation provisions. Further qualifying low-priced share or warrant issuances could trigger additional dilution or reduce warrant exercise prices.
- Other material risks include dependence on third-party manufacturers and clinical research organizations, a sole supplier for drug substance, regulatory and trial uncertainty, patent and license risks, reimbursement and competition. Yissum’s license carries royalties of 4% of net sales and 18% of sublicensing revenue, and may be terminated for uncured defaults.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. It disclosed related-party legal services from a law firm whose senior partner was the Executive Chairman; 2014 payments were approximately $960,409.
- The independent auditor gave an unqualified opinion on the financial statements. Management concluded internal control over financial reporting was effective; the auditor did not express an opinion on internal control.
Important facts for investors to verify
- Confirm the issuer identity and corporate-name history, given the request’s Akari Therapeutics name and the filing’s Celsus Therapeutics name.
- Check subsequent MRX-6 trial results, regulatory status and whether further compliant studies were required.
- Assess cash runway and financing needs against actual operating cash use, and review subsequent financing, dilution and any anti-dilution triggers.
- Review the underlying financial statements and notes for warrant-liability accounting, related-party transactions, lease commitments and Yissum license obligations.
- Verify current patent coverage, manufacturing arrangements and any changes in suppliers, clinical partners or strategic licensing plans.